Selinexor is currently being used in several clinical trials for cancer and has shown anti-cancer effects in combination with other chemotherapies. Clinical trials evaluating the use of selinexor in the treatment of triple negative breast cancer are limited, but in vitro studies show promising results in its ability to kill triple negative breast cancer cells. The mechanism by which this occurs, however, is not understood. The goal of this research was to determine the mechanism by which selinexor kills BT- 549 triple negative breast cancer cells.
Dr. Marilyn Odom
Lawrence, Erin, "Selinexor Hyperactivates Akt and Induces Its Nuclear Accumulation" (2020). Honors Theses. 13.